V1rc31 Inhibitors
V1rc31 inhibitors are a distinct class of chemical compounds designed to selectively inhibit the activity of the V1rc31 protein. This protein, known for its involvement in various biological processes, serves as the target for this class of inhibitors. The chemical design of V1rc31 inhibitors involves an intricate interplay of structural features that enable these compounds to interact specifically with the V1rc31 protein. These inhibitors typically feature a diverse array of chemical scaffolds, such as heterocycles, aromatic rings, and functional groups, which are engineered to optimize binding affinity and specificity.
The development of V1rc31 inhibitors often involves advanced methodologies like high-throughput screening and structure-based drug design. By utilizing the three-dimensional structure of the V1rc31 protein, chemists can craft inhibitors that fit precisely into the protein's active site or other relevant regions, thereby disrupting its function. The chemical modifications in these inhibitors are aimed at enhancing their interaction with V1rc31 while minimizing interactions with other cellular components. This precision in design underscores the complexity of developing effective inhibitors, as even small changes in the chemical structure can significantly impact the binding dynamics and efficacy of the compounds. The variety in chemical frameworks within this class reflects the ongoing efforts to refine and optimize inhibitors for targeted action against V1rc31.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Clomiphene Citrate | 50-41-9 | sc-205636 sc-205636A | 1 g 5 g | $82.00 $173.00 | 1 | |
Clomiphene, an estrogen receptor modulator, may indirectly impact Vmn1r7 by influencing hormonal signaling pathways. As a potential endocrine disruptor, clomiphene could alter the regulation of pheromone receptors, affecting their binding activity and downstream responses. | ||||||
Gallein | 2103-64-2 | sc-202631 | 50 mg | $83.00 | 20 | |
Gallein, a G protein-coupled receptor (GPCR) inhibitor, may directly interfere with GPCR signaling pathways associated with Vmn1r7. By inhibiting downstream cascades, gallein could disrupt pheromone receptor activity and response pathways integral to Vmn1r7 function. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide, a protein synthesis inhibitor, may impact Vmn1r7 indirectly by influencing the synthesis of proteins involved in pheromone signaling. Disruption of protein synthesis could modulate the expression or function of components essential for proper Vmn1r7 activity. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
BAPTA-AM, a calcium chelator, may directly affect Vmn1r7 by altering intracellular calcium concentrations. Given the importance of calcium signaling in pheromone responses, BAPTA-AM could disrupt the receptor's activity by modulating calcium-dependent processes. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $442.00 | 3 | |
Pertussis toxin, an inhibitor of Gi/o proteins, may directly interfere with G protein signaling pathways linked to Vmn1r7. By blocking Gi/o proteins, pertussis toxin could disrupt downstream signaling events, potentially influencing the pheromone receptor activity of Vmn1r7. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin, an adenylate cyclase activator, may indirectly influence Vmn1r7 by modulating cAMP levels. As cAMP is a key second messenger in GPCR signaling, forskolin could alter the intracellular milieu, potentially affecting the pheromone binding and receptor activity of Vmn1r7. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a phosphoinositide 3-kinase (PI3K) inhibitor, may directly impact Vmn1r7 by interfering with PI3K-dependent signaling pathways. As PI3K signaling is implicated in various cellular processes, LY294002 could modulate the pheromone receptor activity and downstream responses of Vmn1r7. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $149.00 $210.00 $714.00 $2550.00 $10750.00 $21410.00 $40290.00 | 5 | |
Suramin, a GPCR antagonist, may directly interfere with Vmn1r7 by inhibiting GPCR signaling pathways. By blocking GPCR activation, suramin could disrupt downstream cascades, potentially affecting the pheromone binding and receptor activity of Vmn1r7. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
KN-93, a calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor, may directly impact Vmn1r7 by interfering with CaMKII-dependent signaling pathways. As CaMKII is involved in calcium-mediated signaling, KN-93 could modulate the pheromone receptor activity of Vmn1r7 by affecting downstream events. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059, a MEK inhibitor, may indirectly influence Vmn1r7 by disrupting the MAPK/ERK signaling pathway. As this pathway is implicated in GPCR signaling, PD98059 could modulate downstream events, potentially affecting the pheromone receptor activity and responses of Vmn1r7. | ||||||